Thank you, Mr. Chair.
First, because it is the national holiday in Quebec and the festivities have begun, I would like to wish all the Quebeckers here a happy National Holiday. Unfortunately, there are not many of them.
We can still take an interest in issues such as the provinces' sole jurisdiction over long‑term care centres. However, that is not what we are talking about right now. It is about the hierarchy of law.
Does constitutional law trump statutory law? Why are the government and some officials pitting the prerogatives of Parliament against those of personal information? That's what I'm wondering about.
Let me also refer to section 18 of the Constitution Act, 1867:
The privileges, immunities, and powers to be held, enjoyed, and exercised by the Senate and by the House of Commons, and by the members thereof respectively, shall be such as are from time to time defined by Act of the Parliament of Canada, but so that any Act of the Parliament of Canada defining such privileges, immunities, and powers shall not confer any privileges, immunities, or powers exceeding those at the passing of such Act held, enjoyed, and exercised by the Commons House of Parliament of the United Kingdom of Great Britain and Ireland, and by the members thereof.
I would also like to mention Standing Order 108(1)(a), which refers to the powers of standing committees:
Standing committees shall be severally empowered to examine and enquire into all such matters as may be referred to them by the House, to report from time to time, and except when the House otherwise orders, to send for persons, papers and records, to sit while the House is sitting, to sit during periods when the House stands adjourned, to sit jointly with other standing committees, to print from day to day such papers and evidence as may be ordered by them, and to delegate to subcommittees all or any of their powers except the power to report directly to the House.
Mr. Chair, I thought it is helpful to share this with you, especially as it relates to the study that we should be doing now. For me, it is really of national interest to know how much Canadians are paying for vaccines. We are talking about supply and demand, an issue that has an impact on the world.
We know that Canada's first problem was that we didn't have a domestic vaccine production capability. So we found ourselves completely dependent on the international market. If supply and demand cause prices to fluctuate, will the price of a vaccine purchased when it first became available in December, and the price of a vaccine purchased this summer be the same? Consequently, did the vaccine cost more at the beginning because the government wanted to put on a show for the cameras? Can we have the exact information?
What we have learned from the budget is that $9 billion was apparently allocated for the purchase of vaccines. If we can compare supply and demand, would we be able to have more information?
This is a public policy issue. The difficulty in being able to analyze the actual price of the vaccines—because the documents were redacted by the department instead of being sent to a law clerk who would have redacted them, according to the rules of the motion—is really interesting. According to a February 5 article, Canada paid more to be at the top of Pfizer's and Moderna's delivery lists in December, paying an average of $37.70 per vaccine, according to data released by Statistics Canada.
At a committee meeting, I asked Mr. Pinnow, the president of Pfizer Canada, just how the supply and demand factor influences the price of a vaccine. He replied, “Pfizer has been on record from the beginning to say that traditional supply and demand economics do not factor into our pricing decision.”
I then asked him whether the price of a vaccine purchased by the Government of Canada or any other country in the last quarter of 2020, in December, would be higher or lower than if the vaccine were purchased in summer 2021, when there's less demand. Mr. Pinnow answered: “Again, I appreciate the question, but we will not be discussing pricing publicly.”
So we are really in a position where parliamentary privilege does not apply. This is about the best interests of the public, the public interest in knowing how much the whole COVID‑19 pandemic will have cost. We are given no answers, but I think that knowing the data is absolutely essential.
Statistics Canada, in an analysis of international merchandise trade for the month of December 2020, tells us the following: “Based on a preliminary analysis, it is estimated that Canada's imports of COVID‑19 vaccines totalled approximately $16 million in December.” Is this number good or bad? Could we find out?
As of December 30, Ottawa had received 424,150 doses from Pfizer and Moderna. The government declined to say how much it had paid for each one, but Statistics Canada's analysis put us back at $37.70.
However, Canada also received its first vials in time for Christmas, shortly after the U.K., but before the European Union. It made for great television in Canada and other countries to see seniors finally getting the vaccine.
However, according to figures released by a Belgian MP last month, the European Union paid far less for those doses than Canada—$22.91 for Moderna and $18.47 for Pfizer. The U.S. also paid less than us, $24.80 for Pfizer doses and $35 for Moderna doses, according to data published by Washington and Forbes magazine. The Europeans and Americans are vaccine producers.
Canada is not because we have given up our ability to produce vaccines. Fortunately, we may take some symbolic steps towards producing vaccines, but that will probably be after all Canadians have been vaccinated. The Americans and Europeans have ordered more vials than Canada and they have production facilities at home. These two factors influence prices. In this regard, I would like to know whether we, as taxpayers, have paid the right price for what we received, and especially whether the government will remember that depending on other vaccine‑producing countries has put us in a weak position. The same is true for personal protective equipment.
We are entering another phase with the Patented Medicine Prices Review Board (PMPRB), where we are still totally dependent on the prices in other countries. Is there anything we can do about it?
Transparency, meaning not having redacted documents, would allow us to make informed decisions in the best interests of the people we represent.
My hypothesis is that we have paid far too much and that the pharmaceutical companies have made a lot of money on the backs of Canadian taxpayers. Of course, we are in a pandemic and the debt is over $1 trillion. The amount of money is very relative, but I think it is essential to have responsible management. Perhaps that is what we do not have.
I remind you of the urgency of making sure that Canada's plants can be used and that our researchers can do research by applying basic science. We need to fund the entire vaccine chain, the ecosystem, as Mr. Lamarre said to the committee last week. We have missed the boat in many ways, and ultimately, we should ask whether the money we overpaid for vaccines could have been invested in producing our own vaccines.
I think those questions answer themselves. However, I'm not a scientist, I'm a parliamentarian. I would like to be able to rely on very tangible data to have these things clear in my head. But the government is not allowing us to have the data at this time. It seems to me that it would be irresponsible to run an election campaign on such a fundamental issue: have we paid too much for vaccines?
In that sense, I support the motion.